Cargando…

Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers

CONTEXT: Bitter taste, as well as dissolve time, presents a significant challenge for the acceptability of formulations for oral transmucosal drug delivery. OBJECTIVE: To characterize a novel sublingual tablet formulation of buprenorphine/naloxone with regards to pharmacokinetics, dissolve time and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fischer, Andreas, Jönsson, Martin, Hjelmström, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364559/ https://www.ncbi.nlm.nih.gov/pubmed/24099551 http://dx.doi.org/10.3109/03639045.2013.846365

Ejemplares similares

Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization
por: Gu, Meng, et al.
Publicado: (2023)

Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film
por: Gunderson, Erik W., et al.
Publicado: (2016)

New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone
por: Soyka, Michael
Publicado: (2015)

Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series
por: Martin, Yvette N., et al.
Publicado: (2019)

Sublingual Buprenorphine/Naloxone and Multi-Modal Management for High-Risk Chronic Pain Patients
por: Kaski, Shane, et al.
Publicado: (2021)

Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study
por: Hoffman, Kent, et al.
Publicado: (2017)

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder
por: Dong, Ruihua, et al.
Publicado: (2019)

Preclinical Safety and Pharmacokinetics of Heat Stable Oxytocin in Sublingual Fast-Dissolving Tablet Formulation
por: Zhu, Changcheng, et al.
Publicado: (2022)

Pharmacokinetics of a Prototype Formulation of Sublingual Testosterone and a Buspirone Tablet, Versus an Advanced Combination Tablet of Testosterone and Buspirone in Healthy Premenopausal Women
por: van Rooij, Kim, et al.
Publicado: (2014)

Formulation and Evaluation of New Glimepiride Sublingual Tablets
por: Al-Madhagi, Wafa, et al.
Publicado: (2017)

Validated Spectrophtometric Method for Simultaneous Determination of Buprenorphine and Naloxone in Pharmaceutical Dosage Forms
por: Souri, Effat, et al.
Publicado: (2017)

Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects
por: Hagelberg, Nora M., et al.
Publicado: (2016)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

2198: Gender differences in the pharmacology of buprenorphine sublingual tablets in Hispanics/Latinos: An underrepresented population
por: Ivelisse Santiago, Darlene, et al.
Publicado: (2018)

Pharmacokinetic comparison of two bazedoxifene acetate 20 mg tablet formulations in healthy Korean male volunteers
por: Yeun, Ji-Sun, et al.
Publicado: (2020)

Formulation and evaluation of sublingual tablets containing Sumatriptan succinate
por: Prajapati, Shailesh T, et al.
Publicado: (2012)

Intolerance of sublingual buprenorphine-naloxone during induction in a patient with end-stage liver disease: A case report
por: Behan, Jennifer, et al.
Publicado: (2016)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Reconsidering the Usefulness of Adding Naloxone to Buprenorphine
por: Blazes, Christopher K., et al.
Publicado: (2020)

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy
por: Feng, Hwa‐Ping, et al.
Publicado: (2018)

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis
por: McCormack, Lindsay, et al.
Publicado: (2021)

Disparities in Emergency Department Naloxone and Buprenorphine Initiation
por: Papp, Joan, et al.
Publicado: (2023)

Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico
por: Santiago, Darlene, et al.
Publicado: (2020)

The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers
por: Miller, Bruce E., et al.
Publicado: (2014)

Novel sublingual tablets of Atorvastatin calcium/Trimetazidine hydrochloride combination; HPTLC quantification, in vitro formulation and characterization
por: Atia, Noha N., et al.
Publicado: (2019)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Immediate release tablet formulation of varenicline salicylate and comparative pharmacokinetic study in human volunteers
por: Kwak, Seong Shin, et al.
Publicado: (2018)

Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study
por: McDonald, Rebecca, et al.
Publicado: (2017)

Formulation of sublingual promethazine hydrochloride tablets for rapid relief of motion sickness
por: Alyami, Hamad S, et al.
Publicado: (2021)

Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers
por: Ait Abdellah, Samira, et al.
Publicado: (2023)

Bioequivalence of 2 Naproxen Sodium Tablet Formulations in Healthy Male and Female Volunteers
por: Sugár, Dalma, et al.
Publicado: (2019)

Successful Management of Kratom Use Disorder With Buprenorphine and Naloxone
por: Arhin, Martin, et al.
Publicado: (2023)

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes
por: Lund, Ingunn O., et al.
Publicado: (2013)

Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial
por: Lintzeris, Nicholas, et al.
Publicado: (2021)

The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers
por: Tylleskar, Ida, et al.
Publicado: (2021)

A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
por: Simojoki, Kaarlo, et al.
Publicado: (2008)

Pharmacokinetic Bioequivalence of Two Inhaled Tiotropium Bromide Formulations in Healthy Volunteers
por: Algorta, Jaime, et al.
Publicado: (2016)

Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
por: Costa, Marisa Boff, et al.
Publicado: (2018)

The Bioavailability and Pharmacokinetics of Silymarin SMEDDS Formulation Study in Healthy Thai Volunteers
por: Sornsuvit, Chuleegone, et al.
Publicado: (2018)

Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers
por: Luo, Zhu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_osrif8frq4i2v94ld6svaq56jl